Statistical analysis of possible bias of clinical judgements due to observing an on-therapy marker variable.
In certain double-blind clinical trials there is the possibility that certain 'marker variables' observable during the trial may in part unblind the trial, even at a subliminal level. At issue is whether or not this potential unblinding biases the investigators' clinical efficacy assessments. This issue arose after the completion of three clinical trials that compared tretinoin emollient cream (TEC) 0.05 per cent to its vehicle in patients with photodamaged skin. The question raised was whether or not possible 'subliminal unblinding' of the investigators and patients, due to the cutaneous irritation associated with topical tretinoin, might have caused a treatment bias in the study. To address this issue, we undertook a reanalysis of these three clinical trials. In doing so, we develop in this paper a statistical modelling approach to address issues of possible bias introduced by the ability to observe such marker variables. The approach utilizes a linear discriminant analysis to introduce an auxiliary categorical variable for the efficacy analysis. A suitable categorical data model permits the estimation of relevant bias effects. We illustrate this approach with data from the three TEC 0.05 per cent trials.
Boateng
F
F
R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
Sampson
A
A
Schwab
B
B
D015982:Bias; D016002:Discriminant Analysis; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D006801:Humans; D016014:Linear Models; D015233:Models, Statistical; D010787:Photosensitivity Disorders / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D014212:Tretinoin / Q000627:therapeutic use
D014212:Tretinoin